Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Ravindra, Mittal"'
Autor:
Kairav Kothari, Shreyansh Shah, Vinay Kumar Gill, Rajib Kumar Ray, N. Ravi Kumar, Jayesh Sanmukhani, Pavankumar Daultani, Ravindra Mittal, Trayambak Dutta, Manish Mahajan, Samir Desai
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
Influenza is highly prevalent in children under five years, particularly those under two, accounting for 5–10% of acute respiratory infections (ARIs) in India. This study was conducted to compare the immunogenicity and safety of two tetravalent ina
Externí odkaz:
https://doaj.org/article/b76eb600f65d43059cf8df4204155d19
Autor:
Sumantra Sarkar, Chandrakant Bokade, Kapil Garg, Ravi Kumar, Jayesh Sanmukhani, Ravindra Mittal
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 3, Pp 681-689 (2021)
This phase III clinical trial was conducted to evaluate the immunogenicity and safety of the Tetravalent Influenza Vaccine (Split virion) I.P. (TetIV), containing two strains each of influenza A and B, developed indigenously in the country for the fi
Externí odkaz:
https://doaj.org/article/06a801a926cd405c94ffb3b5c2d969b4
Autor:
Taufik Momin, Kevinkumar Kansagra, Hardik Patel, Sunil Sharma, Bhumika Sharma, Jatin Patel, Ravindra Mittal, Jayesh Sanmukhani, Kapil Maithal, Ayan Dey, Harish Chandra, Chozhavel TM Rajanathan, Hari PR Pericherla, Pawan Kumar, Anjali Narkhede, Deven Parmar
Publikováno v:
EClinicalMedicine, Vol 38, Iss , Pp 101020- (2021)
Background: ZyCoV-D is a DNA vaccine candidate, which comprises a plasmid DNA carrying spike-S gene of SARS-CoV-2 virus along with gene coding for signal peptide. The spike(S) region includes the receptor-binding domain (RBD), which binds to the huma
Externí odkaz:
https://doaj.org/article/a45a671cdc6948cab37598bd0f28efc4
Autor:
Shrikant Sharma, Veer Bahadur Singh, Sanjay Kumar, Vipul Prajapati, Jitendra Patel, Rajesh Vukkala, Sanjay Kumar Jangid, Jayesh Sanmukhani, Gaurav Gupta, Pradip Patel, Ravindra Mittal, Reinhard Glueck
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 6, Pp 1362-1369 (2018)
This phase II / III clinical trial was conducted to evaluate the immunogenicity and safety of the Tetravalent Influenza vaccine (Split virion) I.P. (TetIV) developed indigenously in the country for the first time by M/s Cadila Healthcare Limited, Ind
Externí odkaz:
https://doaj.org/article/b3c336df68fa4446be4c57f90ba70fb3
Autor:
Ashwani Sood, Monjori Mitra, Himanshu Arvind Joshi, Uma Siddhartha Nayak, Prashanth Siddaiah, T. Ramesh Babu, Samarendra Mahapatro, Jayesh Sanmukhani, Gaurav Gupta, Ravindra Mittal, Reinhard Glueck
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 7, Pp 1523-1530 (2017)
This phase III clinical trial was conducted to evaluate the immunogenicity and safety of the single-dose and multi-dose formulations of a novel MMR vaccine (live, freeze-dried) developed by M/s Cadila Healthcare Limited, India (Cadila MMR vaccine), c
Externí odkaz:
https://doaj.org/article/b9ae060bc0ff4ee48c1371088e2ac6db
Autor:
Ambrose Kumar, Kandulna, Kheya Ghosh, Uttam, Shrikant, Sharma, M Ravi, Kumar, K Sivaram, Prasad, Vimal Kant, Goyal, Sanjay Kumar, Jangid, Pavankumar, Daultani, Ravindra, Mittal, Kapil, Maithal
Publikováno v:
Indian Pediatrics. 59:388-392
To evaluate the persistence of antibodies three years after primary vaccination with typhoid conjugate vaccine (TCV) of either Cadila Healthcare Ltd. (Cadila-TCV) or Bharat Biotech International Ltd. (Bharat-TCV) administered in a previous phase II/I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5c01c6387673ad6ea1b63e9b0ee9a4f
https://doi.org/10.1007/s13312-022-2520-7
https://doi.org/10.1007/s13312-022-2520-7
Autor:
Rajesh Joshi, Neeta Hanumante, Uma Nayak, Shalaka Agarkhedkar, Paresh Thakkar, Jayesh Sanmukhani, Ravindra Mittal
Publikováno v:
Journal of Clinical and Diagnostic Research, Vol 12, Iss 1, Pp SC09-SC13 (2018)
Introduction: This is the first study in Indian paediatric subjects to evaluate the novel Measles, Mumps and Rubella (MMR) vaccine developed by M/s Cadila Healthcare Limited, India, containing the Hoshino mumps strain. This phase II study was done as
Externí odkaz:
https://doaj.org/article/8ea10934717b44a8878d720300e2792f
Publikováno v:
South Asian Journal of Cancer, Vol 3, Iss 2, Pp 132-137 (2014)
Background: Despite the advent of 5-HT 3 antagonists, control of delayed gastrointestinal adverse events with cancer chemotherapy is still not optimal. This open label, active controlled, multicentric clinical trial was undertaken to assess the compa
Externí odkaz:
https://doaj.org/article/412b11d472c04945adabe08cb2565a0a
Autor:
RS Kumar, Manish Kumar Jain, Jitendra Singh Kushwaha, Santosh Patil, Vasanti Patil, Soumya Ghatak, Jayesh Sanmukhani, Ravindra Mittal
Publikováno v:
Journal of asthma and allergy. 15
RS Kumar,1 Manish Kumar Jain,2 Jitendra Singh Kushwaha,3 Santosh Patil,4 Vasanti Patil,5 Soumya Ghatak,6 Jayesh Sanmukhani,7 Ravindra Mittal7 1Department of Pulmonary Medicine, Government Medical College & Government General Hospital, Srikakulam, Ind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01bcc74a71c3a553f31a622416d27131
https://pubmed.ncbi.nlm.nih.gov/35712651
https://pubmed.ncbi.nlm.nih.gov/35712651
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
article-version (VoR) Version of Record
This phase III clinical trial was conducted to evaluate the immunogenicity and safety of the Tetravalent Influenza Vaccine (Split virion) I.P. (TetIV), containing two strains each of influenza A and B, developed indigenously in the country for the fi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d78a2957e3ddff3e98456458d9c812f
https://doi.org/10.1080/21645515.2020.1794683
https://doi.org/10.1080/21645515.2020.1794683